Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
A ten percent owner, Reprogrammed Interchange LLC, and Reid Hoffman, a person who may be deemed a beneficial owner of securities held by Reprogrammed Interchange LLC, of Vor Biopharma Inc (NASDAQ:VOR) sold 447,278 shares of common stock on September 16, 2025. The stock, which has shown significant volatility with an 80% gain over the past six months according to InvestingPro data, currently appears undervalued based on Fair Value analysis.
The shares were sold at prices ranging from $1.52 to $1.58, with an average price of $1.5401, for a total value of $688,852. Following the transaction, Reprogrammed Interchange LLC directly holds 32,781,209 shares of Vor Biopharma Inc. Recent InvestingPro analysis shows the company maintains a healthy current ratio of 3.49, though it’s currently experiencing rapid cash burn. Get access to 15+ additional exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Vor Biopharma announced that its shareholders have approved changes to the company’s 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance by 25 million and reducing the annual automatic increase in the share reserve. Additionally, the company has implemented a 1-for-20 reverse stock split, which was approved by stockholders at a special meeting. This reverse split will convert every 20 shares of issued and outstanding common stock into one share, with no change to the par value per share.
Vor Biopharma also announced several changes to its board of directors, with the resignations of Joshua Resnick, M.D., Matthew Patterson, and David Lubner, none of which were due to disagreements with the company. In collaboration news, Vor Biopharma’s partner, RemeGen Co., Ltd, achieved the primary endpoint in a Phase 3 clinical study for telitacicept in adults with IgA nephropathy, showing a significant reduction in the 24-hour urine protein-to-creatinine ratio. Furthermore, Vor Bio is set to present 48-week clinical data from a Phase 3 study of telitacicept in adults with generalized myasthenia gravis at an upcoming medical conference. These developments reflect the company’s ongoing strategic and clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.